Jasper Therapeutics, Inc.
JSPR· Nasdaq
Released Aug 13, 2024, before the open
10-Q filed Aug 13, 2024, 44 days after period end · 0001213900-24-067897
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | -$14.58M | -$16.08M | -$10.40M | -$8.41M |
| EPS Diluted | -$0.97 | -$1.47 | -$0.29 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jasper Therapeutics, Inc. · CIK 1788028 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end
+15.4% from the close of Aug 9, 2024 to the close of Aug 13, 2024, the first after the release.